YolTech’s Founder Interviewed by UCB China Voice Journal

YolTech's founder, Dr. Wu Yuxuan, was recently interviewed by China Voice, the internal journal of UCB, an international leading biopharmaceutical company dedicated to the development and promotion of innovative therapies, with operations in over 40 countries worldwide. As UCB China's internal journal aimed at conveying more voices within the industry to the world, the selection of YolTech for this interview reflects UCB's great attention to the Chinese market and medical innovation.

In the interview, Dr. Wu Yuxuan shared the story of YolTech's establishment and mission. In 2018, after completing his postdoctoral research at Harvard Medical School and returning to China, gene editing was still in its infancy in China. Dr. Wu made the decision to collaborate with Dr. Lu Yuming, who was also in the same laboratory, to create YolTech in Shanghai, the center of the biopharmaceutical ecosystem in the Yangtze River Delta region. In 2022, Dr. Wang Zijun, who had rich experience in LNP-mRNA gene drug development in the United States, joined the team. Driven by the mission of developing revolutionary gene therapies that benefit patients and benefiting from policy support, a large patient base, and a strong talent pool, YolTech only took two years from its establishment to initiating human clinical trials.

At this year's Zhangjiang Life Science International Innovation Summit opening ceremony, Dr. Alexandre MOREAU, UCB China's President, mentioned that China is transforming from the "world's factory" into the "world's brain center," which resonates with YolTech's vision. Dr. Wu expressed his hope for the opportunity to collaborate with UCB to achieve breakthroughs in gene therapy and benefit patients worldwide.

This report demonstrates YolTech's innovative awareness and ambition in the gene therapy field, confidence in the mission of China's medical development, and willingness to collaborate with UCB. Becoming a world-class biopharmaceutical company, providing a platform for employees to strive for their dreams, and seeking well-being for them are YolTech's unchanged beautiful visions.

About YolTech

YolTech is a pioneering gene editing company dedicated to developing a robust gene editing medicines to treat patients with serious diseases. The company has a rare high-throughput gene editor evolution platform in China. At present, the company's three major technology platforms, Cas enzyme, base editor and lipid nanoparticles (LNP), all have independent intellectual property rights and core patent protection, which can ensure that patents are Free implementation worldwide.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology and neurology. With over 8,700 people in 36 countries, the company generated revenue of €5.5 billion in 2022, and invested ~25% of revenue into research and development annually. UCB is listed on Euronext Brussels (symbol: UCB).

Since UCB’s creation in 1928, innovation and agile entrepreneurship have been in the company’s DNA. Throughout its 90-year journey, UCB has continuously been pushing the boundaries and has never shied away from making bold moves to reinvent itself. This innovation spirit and agility mindset is still UCB’s signatures today and will be for the future.

UCB started its pharmaceutical business operations in China in the early 90s. In 1996, UCB opened its first representative office in Shanghai. UCB leapfrogged to be a fast-growing biopharma company in China with the acquisition of Schwarz Pharma and its Zhuhai plant in 2006, as well as the successful launch of an anti-epileptic drug in the following year.

Head office located in Shanghai, UCB China also has regional offices in Beijing, Chengdu, Guangzhou, and a manufacturing site in Zhuhai. With over 500 employees in China, the company has positively impacted the lives of millions of patients. Looking forward, UCB is making great efforts to bring more innovative products and solutions in immunology, neurology, bone health and rare diseases to create value for more Chinese patients.

Looking forward, UCB is making great efforts to bring more innovative products and solutions to the Chinese market in neurology, immune system and rare diseases to create value for more Chinese patients. With our deep scientific research background, UCB will engage in more open and innovative collaborations in the booming innovation hub of China to benefit more patients in China and even the world.